Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines

In omics sciences, many compounds are measured simultaneously in a sample in a single run. Such analytical performance opens up prospects for improving cellular cancer vaccines and other cell-based immunotherapeutics. This article provides an overview of proteomics technology, known as cell proteomi...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2023-02, Vol.15 (2), p.661
Main Authors: Lokhov, Petr G, Balashova, Elena E, Trifonova, Oxana P, Maslov, Dmitry L, Archakov, Alexander I
Format: Article
Language:English
Subjects:
Antigens
Cancer
cancer vaccine
Cancer vaccines
cell authentication
Cell culture
Cell division
Clinical trials
Genomes
Genotype & phenotype
Immune system
Immunotherapy
Mass spectrometry
Methods
Peptides
Pharmaceutical research
Proteins
proteomic footprint
Proteomics
quality control
Review
Scientific imaging
Senescence
vaccination
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In omics sciences, many compounds are measured simultaneously in a sample in a single run. Such analytical performance opens up prospects for improving cellular cancer vaccines and other cell-based immunotherapeutics. This article provides an overview of proteomics technology, known as cell proteomic footprinting. The molecular phenotype of cells is highly variable, and their antigenic profile is affected by many factors, including cell isolation from the tissue, cell cultivation conditions, and storage procedures. This makes the therapeutic properties of cells, including those used in vaccines, unpredictable. Cell proteomic footprinting makes it possible to obtain controlled cell products. Namely, this technology facilitates the cell authentication and quality control of cells regarding their molecular phenotype, which is directly connected with the antigenic properties of cell products. Protocols for cell proteomic footprinting with their crucial moments, footprint processing, and recommendations for the implementation of this technology are described in this paper. The provided footprints in this paper and program source code for their processing contribute to the fast implementation of this technology in the development and manufacturing of cell-based immunotherapeutics.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics15020661